Dyno Therapeutics

Associate Director, Medical Science Liaison - Northeast, South, Central, or West Regions

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Position Overview

  • Location Type: Field-Based (Territory Specific)
  • Job Type: Full-Time
  • Salary: Not specified

The Associate Director, Medical Science Liaison (MSL) is an experienced field medical expert who plays a strategic role on the field medical team with depth and breadth of business acumen, therapeutic knowledge and serves as an informal leader on the team. The person in this role will be a customer facing, field-based extension of our Medical Affairs team. The MSL’s key objective is to create impact through advancing clinical practice within the assigned territory that leads to improved patient outcomes. This individual will serve as a key scientific resource, engaging with healthcare professionals (HCPs), key opinion leaders (KOLs), and other stakeholders to provide scientific and clinical support for our portfolio.

Responsibilities

  • Builds awareness of the company within the medical community and develops strategic KOL/territory engagement plans aligned with the medical strategy.
  • Supports clinical research (investigator-initiated and company-sponsored), speaker development, and training as needed.
  • Demonstrates thorough knowledge of the company, its investigational products, and current medical research.
  • Maximizes attendance at national and regional conferences to gather insights, assess the competitive landscape, and strengthen relationships.
  • Collaborates cross-functionally (clinical, regulatory, market access) to advance business and scientific goals.
  • Develops and executes regional medical strategies in alignment with company goals.
  • Leads KOL engagement strategies and identifying new scientific leaders.
  • Demonstrates business acumen within therapeutic area and understands broader organization and competitive landscape.
  • Establishes and develops HCP relationships, engaging in activities such as data discussions, clinical trials, and addressing patient journey barriers.
  • Responds to unsolicited information requests in a timely, accurate, and compliant manner.
  • Ensures compliant dissemination of scientific and clinical information to healthcare providers.
  • Manages administrative tasks (e.g., Veeva CRM, expense reports, compliance modules) efficiently, including customer profiling and keeping CRM information up to date.

Requirements

  • Advanced scientific degree or equivalent required (e.g., MD, PhD, NP, PharmD, PA)
  • 8+ years of MSL experience
  • Clinical experience within neuromuscular disorders (e.g., DMD, DM1) preferred; rare disease experience considered
  • Strong knowledge of investigational products and the neuromuscular space, including emerging data
  • In-depth understanding of clinical trial and investigator-sponsored study processes
  • Proven ability to work effectively within multidisciplinary teams
  • Clear understanding of MSL role and responsibilities
  • Skilled in building and maintaining relationships with KOLs through scientific expertise and follow-through
  • Able to communicate research results clearly to diverse audiences
  • Strong communication skills (written, verbal, presentation) for building relationships with colleagues
  • Expert in planning, prioritizing, and executing tasks efficiently
  • Capable of working independently and managing time in a home office
  • Adaptable in ambiguous and dynamic environments
  • Leverages past neuromuscular relationships to support study enrollment

Company Information

Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

Skills

Medical Science
KOL engagement
Clinical Research
Medical Affairs
Scientific Communication
Strategic Planning
Therapeutic Knowledge
HCP engagement

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.
Manufacturing bottlenecks could hinder scaling of Dyno's operations.
Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.
Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.
Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.
Collaboration with NVIDIA enhances biological sequence design for gene therapies.
Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI